|
KMID : 0939920160480010393
|
|
대한암학회지
2016 Volume.48 No. 1 p.393 ~ p.397
|
|
|
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
|
|
Jo Jae-Min
Kim Jung-Ho
Kim Ji-Young
Hyun Chang-Lim
Rhee Ji-Young
Kwon Jung-Mi
Han Sang-Hoon
Kim Woo-Kun
|
|
|
Abstract
|
|
|
|
Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors’ knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.
|
|
|
KEYWORD
|
|
|
Lung neoplasms, Drug therapy, Tyrosine kinase inhibitor, Pazopanib
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|